Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol - Concepedia

Concepedia

Publication | Open Access

Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in <i>GBA</i>-associated Parkinson’s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol

DOI Full Paper Access

27

Citations

45

References

2023

Year

Fabiana Colucci, Micol Avenali, Rosa De Micco, M. Poli, Silvia Cerri, Mario Stanziano, Ana Bacila, Giada Cuconato, Valentina Franco, Diego Franciotta,

BMJ Neurology Open

Abstract

NCT05287503, EudraCT 2021-004565-13.

References

	Year	Citations

Page 1